Last updated on July 2018

A Study to Assess the Effect of AZD5634 on Mucociliary Clearance Safety Tolerability and Pharmacokinetic Parameters in Patients With Cystic Fibrosis


Brief description of study

This study will assess the effect of inhaled AZD5634 on Mucociliary clearance (MCC) in patients with Cystic fibrosis (CF) after single-dose administration.

Detailed Study Description

The primary pharmacodynamic endpoint will be the average whole lung particle clearance between 0 and 60 minutes after administration of aerosolized radiolabelled particles (colloids) at Visits 2 and 3 (%MCC 0-60, whole).

Clinical Study Identifier: NCT02950805

Contact Investigators or Research Sites near you

Start Over

AstraZeneca Clinical Study Information Center

Research Site
Birmingham, AL United States

AstraZeneca Clinical Study Information Center

Research Site
Baltimore, MD United States

AstraZeneca Clinical Study Information Center

Research Site
Chapel Hill, NC United States

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.